QTX3544-201 A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients with Advanced Solid Tumors with KRASG12V Mutations
Clinical Trial Grant
Awarded By
Quanta Therapeutics, Inc.
Start Date
May 5, 2025
End Date
May 31, 2030
Awarded By
Quanta Therapeutics, Inc.
Start Date
May 5, 2025
End Date
May 31, 2030